BioLife HSR waiting period expires for Repligen acquisition; vote set for Oct 5

BIOLIFE SOLUTIONS INC

HSR waiting period expired Sept 3, 2026, clearing antitrust condition for Repligen merger.
Deal consideration: $11.25 cash + 0.1442 Repligen shares per BioLife share.
Special stockholder meeting to vote on merger scheduled Oct 5, 2026 at 9:00 a.m. ET.
Merger still subject to other closing conditions, including BioLife stockholder approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.